BSCI-12. Inhibition of melanoma brain metastasis by targeting miR-146a

BACKGROUND: Melanoma has the highest propensity of any cancer to metastasize to the brain, with late-stage patients developing brain metastasis (MBM) in 40% of cases. Survival of patients with MBM is around 8 months with current therapies, illustrating the need for new treatments. MBM development is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiwei, Rigg, Emma, Lunavat, Taral R, Zhou, Wenjing, Feng, Zichao, Hoang, Tuyen, Bjerkvig, Rolf, Thorsen, Frits
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351179/
http://dx.doi.org/10.1093/noajnl/vdab071.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351179/
http://dx.doi.org/10.1093/noajnl/vdab071.011

Ejemplares similares